Journal article
POSNOC-POsitive Sentinel NOde: Adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes
A Goyal, GB Mann, L Fallowfield, L Duley, M Reed, D Dodwell, RE Coleman, A Fakis, R Newcombe, V Jenkins, D Whitham, M Childs, D Whynes, V Keeley, I Ellis, P Fairbrother, S Sadiq, K Monson, A Montgomery, W Tan Show all
BMJ Open | BMJ PUBLISHING GROUP | Published : 2021
Abstract
Introduction ACOSOG-Z0011(Z11) trial showed that axillary node clearance (ANC) may be omitted in women with ≤2 positive nodes undergoing breast conserving surgery (BCS) and whole breast radiotherapy (RT). A confirmatory study is needed to clarify the role of axillary treatment in women with ≤2 macrometastases undergoing BCS and groups that were not included in Z11 for example, mastectomy and those with microscopic extranodal invasion. The primary objective of POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy (POSNOC) is to evaluate whether for women with breast cancer and 1 or 2 macrometastases, adjuvant therapy alone is non-inferi..
View full abstractGrants
Awarded by Health Technology Assessment Programme
Funding Acknowledgements
The trial is sponsored by the University Hospitals of Derby and Burton NHS Foundation Trust(uhdb.sponsor@nhs.net).Sponsor staff -Daniel Davis, Joanne Thornhill, Anne Shaw, Amy Farmer, Teresa Grieve. This project is funded by the National Institute for Health Research Health Technology Assessment Programme (project number 12/35/17). Australian and New Zealand participation is funded by National Health and Medical Research Council (NHMRC) (project grant 1083172).